Erasca (ERAS) Competitors $1.22 -0.06 (-4.69%) Closing price 04:00 PM EasternExtended Trading$1.25 +0.03 (+2.87%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. INDV, EWTX, JANX, EVO, IMCR, MESO, ADPT, VERA, DYN, and GPCRShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Indivior (INDV), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Evotec (EVO), Immunocore (IMCR), Mesoblast (MESO), Adaptive Biotechnologies (ADPT), Vera Therapeutics (VERA), Dyne Therapeutics (DYN), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Indivior Edgewise Therapeutics Janux Therapeutics Evotec Immunocore Mesoblast Adaptive Biotechnologies Vera Therapeutics Dyne Therapeutics Structure Therapeutics Erasca (NASDAQ:ERAS) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk. Which has more volatility & risk, ERAS or INDV? Erasca has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Do analysts recommend ERAS or INDV? Erasca presently has a consensus price target of $4.57, suggesting a potential upside of 274.71%. Indivior has a consensus price target of $15.00, suggesting a potential upside of 32.86%. Given Erasca's higher possible upside, analysts clearly believe Erasca is more favorable than Indivior.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Indivior 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the MarketBeat Community prefer ERAS or INDV? Erasca received 19 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 73.17% of users gave Erasca an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes3073.17% Underperform Votes1126.83% IndiviorOutperform Votes11100.00% Underperform VotesNo Votes Do institutionals & insiders believe in ERAS or INDV? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 14.4% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has stronger valuation & earnings, ERAS or INDV? Indivior has higher revenue and earnings than Erasca. Indivior is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.62-1.97Indivior$1.17B1.33$2M-$0.31-36.42 Does the media favor ERAS or INDV? In the previous week, Erasca had 5 more articles in the media than Indivior. MarketBeat recorded 8 mentions for Erasca and 3 mentions for Indivior. Indivior's average media sentiment score of 1.72 beat Erasca's score of 1.00 indicating that Indivior is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indivior 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is ERAS or INDV more profitable? Erasca has a net margin of 0.00% compared to Indivior's net margin of -3.96%. Erasca's return on equity of -42.26% beat Indivior's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -42.26% -34.97% Indivior -3.96%-241.73%15.09% SummaryErasca beats Indivior on 10 of the 18 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$345.61M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-1.478.9226.8419.71Price / SalesN/A250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book0.586.466.794.50Net Income-$125.04M$143.98M$3.23B$248.18M7 Day Performance-3.94%3.04%4.07%1.14%1 Month Performance-1.61%7.44%12.52%15.18%1 Year Performance-48.09%-2.46%16.83%6.55% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca3.6125 of 5 stars$1.22-4.7%$4.57+274.7%-42.9%$345.61MN/A-1.47120Gap UpINDVIndivior3.28 of 5 stars$11.34+2.3%$15.00+32.3%-33.1%$1.56B$1.17B-32.401,164News CoveragePositive NewsEWTXEdgewise Therapeutics2.9231 of 5 stars$14.82+1.6%$40.22+171.4%-20.8%$1.55BN/A-9.8860Positive NewsJANXJanux Therapeutics2.7447 of 5 stars$26.06+2.0%$95.25+265.5%-47.1%$1.54B$10.59M-22.2730Positive NewsEVOEvotec1.4939 of 5 stars$4.17-3.0%$5.93+42.3%-21.9%$1.48B$788.22M0.004,200Positive NewsIMCRImmunocore2.9167 of 5 stars$29.54+4.0%$58.13+96.8%-39.1%$1.48B$310.20M-31.09320Positive NewsMESOMesoblast1.8344 of 5 stars$11.35+3.5%$18.00+58.6%+57.9%$1.45B$5.67M0.0080Gap DownADPTAdaptive Biotechnologies3.5631 of 5 stars$9.51+5.3%$9.83+3.4%+160.7%$1.44B$189.53M-8.72790News CoveragePositive NewsVERAVera Therapeutics3.3651 of 5 stars$22.49+3.6%$63.33+181.6%-48.2%$1.43BN/A-8.6240Positive NewsDYNDyne Therapeutics3.7405 of 5 stars$12.56+10.1%$46.85+273.0%-65.1%$1.43BN/A-3.53100Positive NewsGap DownHigh Trading VolumeGPCRStructure Therapeutics2.1255 of 5 stars$24.62-3.7%$78.00+216.8%-31.1%$1.41BN/A-33.27136Gap Up Related Companies and Tools Related Companies Indivior Alternatives Edgewise Therapeutics Alternatives Janux Therapeutics Alternatives Evotec Alternatives Immunocore Alternatives Mesoblast Alternatives Adaptive Biotechnologies Alternatives Vera Therapeutics Alternatives Dyne Therapeutics Alternatives Structure Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ERAS Stock Free ERAS Stock Alerts